Sofinicline: a novel nicotinic acetylcholine receptor agonist in the treatment of attention-deficit/hyperactivity disorder

Bibliography

• Wolraich ML, McKeown RE, Visser SN, et al. The prevalence of ADHD: its diagnosis and treatment in four school districts across two states. J Atten Disord 2012. [ Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Kessler RC, Adler L, Barkley R, et al. The prevalence and correlates of adult ADHD in the United States: results from the National Comorbidity Survey Replication. Am J Psychiatry 2006;163:716-23
   PubMed Web of Science ®Google Scholar
• Fayyad J, De Graaf R, Kessler R, et al. Cross-national prevalence and correlates of adult attention-deficit hyperactivity disorder. Br J Psychiatry 2007;190:402-9
   PubMed Web of Science ®Google Scholar
• Pliszka S; AACAP Work Group on Quality Issues. Practice parameter for the assessment and treatment of children and adolescents with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 2007;46:894-921
   PubMed Web of Science ®Google Scholar
• Faraone SV. Using meta-analysis to compare the efficacy of medications for attention-deficit/hyperactivity disorder in youths. P T 2009;34:678-94
   PubMedGoogle Scholar
• Molina BSG, Hinshaw SP, Swanson JM, et al. The MTA at 8 years: prospective follow-up of children treated for combined-type ADHD in a multisite study. J Am Acad Child Adolesc Psychiatry 2009;48:484-500
   PubMed Web of Science ®Google Scholar
• Spencer TJ, Wilens TE, Biederman J, et al. Efficacy and safety of mixed amphetamine salts extended release (Adderall XR) in the management of attention-deficit/hyperactivity disorder in adolescent patients: a 4-week, randomized, double-blind, placebo-controlled, parallel-group study. Clin Ther 2006;28:266-79
   PubMed Web of Science ®Google Scholar
• Toomey SL, Sox CM, Rusinak D, Finkelstein JA. Why do children with ADHD discontinue their medication? Clin Pediatr (Phila) 2012;51:763-9
   PubMed Web of Science ®Google Scholar
• Kollins SH. A qualitative review of issues arising in the use of psycho-stimulant medications in patients with ADHD and co-morbid substance use disorders. Curr Med Res Opin 2008;24:1345-57
   PubMed Web of Science ®Google Scholar
• Charach A, Fernandez R. Enhancing ADHD medication adherence: challenges and opportunities. Curr Psychiatry Rep 2013;15(7):371
   PubMed Web of Science ®Google Scholar
• Pliszka SR, Crismon ML, Hughes CW, et al. The Texas Children’s Medication Algorithm Project: revision of the algorithm for pharmacotherapy of attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 2006;45:642-57
   PubMed Web of Science ®Google Scholar
• Faraone SV, Glatt SJ. A comparison of the efficacy of medications for adult attention-deficit/hyperactivity disorder using meta-analysis of effect sizes. J Clin Psychiatry 2010;71:754-63
   PubMed Web of Science ®Google Scholar
• Sallee F, Connor DF, Newcorn JH. A review of the rationale and clinical utilization of alpha2-adrenoceptor agonists for the treatment of attention-deficit/hyperactivity and related disorders. J Child Adolesc Psychopharmacol 2013;23:308-19
   PubMed Web of Science ®Google Scholar
• Moriyama TS, Polanczyk GV, Terzi FS, et al. Psychopharmacology and psychotherapy for the treatment of adults with ADHD-a systematic review of available meta-analyses. CNS Spectr 2013;18:296-306
   PubMed Web of Science ®Google Scholar
• Stahl SM, Mignon L. Attention deficit hyperactivity disorder. Cambridge University Press, Cambridge, New York; 2010
   Google Scholar
• Levin ED, McClernon FJ, Rezvani AH. Nicotinic effects on cognitive function: behavioral characterization, pharmacological specification, and anatomic localization. Psychopharmacology (Berl) 2006;184:523-39
   PubMed Web of Science ®Google Scholar
• Levin ED, Cauley M, Rezvani AH. Improvement of attentional function with antagonism of nicotinic receptors in female rats. Eur J Pharmacol 2013;702:269-74
   PubMed Web of Science ®Google Scholar
• Potter AS, Ryan KK, Newhouse PA. Effects of acute ultra-low dose mecamylamine on cognition in adult attention-deficit/hyperactivity disorder (ADHD). Hum Psychopharmacol 2009;24:309-17
   PubMed Web of Science ®Google Scholar
• Levin ED, Caldwell DP. Low-dose mecamylamine improves learning of rats in the radial-arm maze repeated acquisition procedure. Neurobiol Learn Mem 2006;86:117-22
   PubMed Web of Science ®Google Scholar
• Buccafusco JJ, Jackson WJ, Terry AV Jr, et al. Improvement in performance of a delayed matching-to-sample task by monkeys following ABT-418: a novel cholinergic channel activator for memory enhancement. Psychopharmacology (Berl) 1995;120:256-66
   PubMed Web of Science ®Google Scholar
• Vidal C. Nicotinic receptors in the brain. Molecular biology, function, and therapeutics. Mol Chem Neuropathol 1996;28:3-11
   PubMedGoogle Scholar
• Dunbar GC, Kuchibhatla R. Cognitive enhancement in man with ispronicline, a nicotinic partial agonist. J Mol Neurosci 2006;30:169-72
   PubMed Web of Science ®Google Scholar
• Hosford D, Dunbar G, Lieberman JA, Segreti A. The alpha7 neuronal nicotinic receptor (NNR) modulator TC-5619 had beneficial effects and was generally well tolerated in a Phase 2 trial in cognitive dysfunction in schizophrenia (CDS). American College of Neuropsychopharmacology; 2011. Waikoloa, Hawaii
   Google Scholar
• Prendergast MA, Jackson WJ, Terry AV Jr, et al. Central nicotinic receptor agonists ABT-418, ABT-089, and (-)-nicotine reduce distractibility in adult monkeys. Psychopharmacology (Berl) 1998;136:50-8
   PubMed Web of Science ®Google Scholar
• Apostol G, Abi-Saab W, Kratochvil CJ, et al. Efficacy and safety of the novel alpha4beta2 neuronal nicotinic receptor partial agonist ABT-089 in adults with attention-deficit/hyperactivity disorder: a randomized, double-blind, placebo-controlled crossover study. Psychopharmacology (Berl) 2011;219:715-25
   PubMed Web of Science ®Google Scholar
• Bain EE, Apostol G, Sangal RB, et al. A randomized pilot study of the efficacy and safety of ABT-089, a novel alpha4beta2 neuronal NICOTINIC receptor agonist, in adults with attention-deficit/hyperactivity disorder. J Clin Psychiatry 2012;73:783-9
   PubMed Web of Science ®Google Scholar
• Wilens TE, Verlinden MH, Adler LA, et al. ABT-089, a neuronal nicotinic receptor partial agonist, for the treatment of attention-deficit/hyperactivity disorder in adults: results of a pilot study. Biol Psychiatry 2006;59:1065-70
   PubMed Web of Science ®Google Scholar
• Wilens TE, Gault LM, Childress A, et al. Safety and efficacy of ABT-089 in pediatric attention-deficit/hyperactivity disorder: results from two randomized placebo-controlled clinical trials. J Am Acad Child Adolesc Psychiatry 2011;50:73-84.e1
   PubMed Web of Science ®Google Scholar
• Potter AS, Dunbar G, Mazzulla E, et al. AZD3480, a novel nicotinic receptor agonist, for the treatment of attention-deficit/hyperactivity disorder in adults. Biol Psychiatry 2014;75:207-14
   PubMed Web of Science ®Google Scholar
• Scheffler RM, Hinshaw SP, Modrek S, Levine P. The global market for ADHD medications. Health Aff (Millwood) 2007;26:450-7
   PubMed Web of Science ®Google Scholar
• ORADUR®-ADHD Program. Products. Durect Corp., Cupertino, CA; 2013. Available from: http://www.durect.com/wt/durect/page_name/oradur_adhd [Last accessed 12 January 2014]
   Google Scholar
• Nicotinics Monthly. UpdatesPlus. LeadDiscovery, Bodiam, UK; 2012. Available from: http://www.leaddiscovery.co.uk/admin/upload/files/%20UpdatesPlus-Nicotinics-Sept-Oct12%20example.pdf [Last accessed 18 January 2014]
   Google Scholar
• NeuroSearch: ABT-894 remains viable option for ADHD following neuropathic pain failure. News. Datamonitor Research Store, New York, NY; 2009. Available from: http://www.datamonitor.com/store/News/neurosearch_abt_894_remains_ viable_option_for_adhd_following_neuropathic_pain_failure?productid=2D5D97F8-CBDA-4B2D-A291-253ADB570F10 [Last accessed 12 February 2014]
   Google Scholar
• Ji J, Schrimpf MR, Sippy KB, et al. Synthesis and structure-activity relationship studies of 3,6-diazabicyclo[3.2.0]heptanes as novel alpha4beta2 nicotinic acetylcholine receptor selective agonists. J Med Chem 2007;50:5493-508
   PubMed Web of Science ®Google Scholar
• Sofinicline, CID= 10131048. Compound Summary. National Institutes of Health, National Center for Biotechnology Information, PubChem Compound Database. Washington, DC; 2014. Available from: http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=10131048 [Last accessed 12 January 2014]
   Google Scholar
• Wilens TE, Decker MW. Nueronal nicotinic receptor agonists for the treatment of attention-deficit/hyperactivity disorder: focus on cognition. Biochem Pharmacol 2007;74:1212-23
   PubMed Web of Science ®Google Scholar
• Bain EE, Abi-Saab WM, Dutta S, et al. Sofinicline (abt-894) for attention-deficit/hyperactivity disorder. WO2009149003 A1; 2009
   Google Scholar
• Bain EE, Robieson W, Pritchett Y, et al. A randomized, double-blind, placebo-controlled phase 2 study of alpha4beta2 agonist ABT-894 in adults with ADHD. Neuropsychopharmacology 2013;38:405-13
   PubMed Web of Science ®Google Scholar
• Rueter LE, Anderson DJ, Briggs CA, et al. ABT-089: pharmacological properties of a neuronal nicotinic acetylcholine receptor agonist for the potential treatment of cognitive disorders. CNS Drug Rev 2004;10:167-82
   PubMedGoogle Scholar
• ABT-894. Other assets. Neurosearch, Copenhagen, Denmark; 2014. Available from: http://neurosearch.com/Default.aspx?ID=8266 [Last accessed 26 March 2014]
   Google Scholar
• Home. ClinicalTrials.gov. National Institutes of Health, Washington, DC; 2014. Available from: http://clinicaltrials.gov/ [Last accessed 26 March 2014]
   Google Scholar
• Home and Search. EU Clinical Trials Register. European Medicines Agency, London, England, UK; 2014. Available from: https://www.clinicaltrialsregister.eu/ctr-search/search;jsessionid=RJjvTJZQfzRH0T8vwWyGcHflpTqWfSDjh03mTQYhyvX5dxRtDWWh!164305626 [Last accessed 26 March 2014]
   Google Scholar
• McClernon FJ, Fuemmeler B, Kollins S, et al. Interactions between genotype and retrospective ADHD symptoms predict lifetime smoking risk in a sasmple of young adults. Nicotine Tob Res 2008;10:117-27
   PubMed Web of Science ®Google Scholar
• Levin ED, Conners CK, Sparrow E, et al. Nicotine effects on adults with attention-deficit/hyperactivity disorder. Psychopharmacology (Berl) 1996;123:55-63
   PubMed Web of Science ®Google Scholar
• Montoya A, Hervas A, Cardo E, et al. Evaluation of atomoxetine for first-line treatment of newly diagnosed, treatment-naïve children and adolescents with attention deficit/hyperactivity disorder. Curr Med Res Opin 2009;25:2745-54
   PubMed Web of Science ®Google Scholar
• Michelson D, Allen AJ, Busner J, et al. Once-daily atomoxetine treatment for children and adolescents with attention deficit hyperactivity disorder: a randomized, placebo-controlled study. Am J Psychiatry 2002;159:1896-901
   PubMed Web of Science ®Google Scholar
• Gau SSF, Huang Y-S, Soong W-T, et al. A randomized, double-blind, placebo-controlled clinical trial on once-daily atomoxetine in Taiwanese children and adolescents with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol 2007;17:447-60
   PubMed Web of Science ®Google Scholar
• Svanborg P, Thernlund G, Gustafsson PA, et al. Efficacy and safety of atomoxetine as add-on to psychoeducation in the treatment of attention deficit/hyperactivity disorder: a randomized, double-blind, placebo-controlled study in stimulant-naïve Swedish children and adolescents. Eur Child Adolesc Psychiatry 2009;18:240-9
   PubMed Web of Science ®Google Scholar
• Michelson D, Adler L, Spencer T, et al. Atomoxetine in adults with ADHD: two randomized, placebo-controlled studies. Biol Psychiatry 2003;53:112-20
   PubMed Web of Science ®Google Scholar
• Sutherland SM, Adler LA, Chen C, et al. An 8-week, randomized controlled trial of atomoxetine, atomoxetine plus buspirone, or placebo in adults with ADHD. J Clin Psychiatry 2012;73:445-50
   PubMed Web of Science ®Google Scholar
• Young JL, Sarkis E, Qiao M, Wietecha L. Once-daily treatment with atomoxetine in adults with attention-deficit/hyperactivity disorder: a 24-week, randomized, double-blind, placebo-controlled trial. Clin Neuropharmacol 2011;34:51-60
   PubMed Web of Science ®Google Scholar
• Jain R, Segal S, Kollins SH, Khayrallah M. Clonidine extended-release tablets for pediatric patients with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 2011;50:171-9
   PubMed Web of Science ®Google Scholar
• Biederman J, Melmed RD, Patel A, et al. A randomized, double-blind, placebo-controlled study of guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder. Pediatrics 2008;121:e73-84
   Google Scholar
• Sallee FR, Lyne A, Wigal T, McGough JJ. Long-term safety and efficacy of guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol 2009;19:215-26
   PubMed Web of Science ®Google Scholar
• Hurst R, Rollema H, Bertrand D. Nicotinic acetylcholine receptors: from basic science to therapeutics. Pharmacol Ther 2013;137:22-54
   PubMed Web of Science ®Google Scholar
• Todd RD, Neuman RJ. Gene-environment interactions in the development of combined type ADHD: evidence for a synapse-based model. Am J Med Genet Part B Neuropsychiatr Genet 2007;144B:971-5
   PubMed Web of Science ®Google Scholar
• Guan L, Wang B, Chen Y, et al. A high-density single-nucleotide polymorphism screen of 23 candidate genes in attention deficit hyperactivity disorder: suggesting multiple susceptibility genes among Chinese Han population. Mol Psychiatry 2009;14:546-54
   PubMed Web of Science ®Google Scholar
• Stergiakouli E, Hamshere M, Holmans P, deCODE Genetics. et al. Investigating the contribution of common genetic variants to the risk and pathogenesis of ADHD. Am J Psychiatry 2012;169:186-94
   PubMed Web of Science ®Google Scholar
• Williams NM, Franke B, Mick E, et al. Genome-wide analysis of copy number variants in attention deficit hyperactivity disorder: the role of rare variants and duplications at 15q13.3. Am J Psychiatry 2012;169:195-204
   PubMed Web of Science ®Google Scholar
• Lee J, Laurin N, Crosbie J, et al. Association study of the nicotinic acetylcholine receptor alpha4 subunit gene, CHRNA4, in attention-deficit hyperactivity disorder. Genes Brain Behav 2008;7:53-60
   PubMed Web of Science ®Google Scholar
• Manor I, Ben-Hayun R, Aharon-Peretz J, et al. A randomized, double-blind, placebo-controlled, multicenter study evaluating the efficacy, safety, and tolerability of extended-release metadoxine in adults with attention-deficit/hyperactivity disorder. J Clin Psychiatry 2012;73:1517-23
   PubMed Web of Science ®Google Scholar
• Alcobra’s ADHD Program Moving To Pediatrics. Alerts. Seeking Alpha, Pittsburgh, PA; 2014. Available from: http://seekingalpha.com/article/1946961-alcobras-adhd-program-moving-to-pediatrics [Last accessed 12 February 2014]
   Google Scholar
• DURECT Announces Selection with Orient PHARMA of Lead Formulation for ORADUR®-Methylphenidate. Press Release. PR Newswire, New York, NY; 2013. Available from: http://www.prnewswire.com/news-releases/durect-announces-selection-with-orient-pharma-of-lead-formulation-for-oradur-methylphenidate-217906421.html [Last accessed 12 January 2014]
   Google Scholar
• Neurovance Raises $7 Million for ADHD Drug Development. Articles. Xconomy, Inc., Cambridge, MA; 2012. Available from: http://www.xconomy.com/boston/%202012/10/19/%20neurovance-raises-7-million-for-adhd-drug-development/ [Last accessed 12 January 2014]
   Google Scholar
• Cincinnati company developing new ADHD drug. Innovation + Startup News. Soapbox Media, Cincinnati, OH; 2012. Available from: http://www.soapboxmedia.com/innovationnews/073112p2d.aspx [Last accessed 12 January 2014]
   Google Scholar
• Product Pipeline: PD2005 for Attention Deficit Hyperactivity Disorder. Products. P2D Bioscience, Cincinnati, OH; 2012. Available from: http://www.p2dinc.com/products.html [Last accessed 12 January 2014]
   Google Scholar
• Targacept to discontinue development of TC-5619 for ADHD, eliminate jobs. Top Story. FirstWordPharma, London, UK; 2012. Available from: http://www.firstwordpharma.com/node/1017523 [Last accessed 11 June 2014]
   Google Scholar
• Safety and Efficacy of GTS21 in Adults With Attention-deficit Hyperactivity Disorder. Clinical Trial. TrialBulletin.com, Haverhill, UK; 2014. Available from: http://trialbulletin.com/lib/entry/ct-00419445 [Last accessed 11 June 2014]
   Google Scholar